We narrowed to 51,260 results for: des.1

#105448-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSyn-DIO-ChrimsonR-mRuby2-ST (#105448). In addition to the viral particles, you will also receive purified pAAV-hSyn-DIO-ChrimsonR-mRuby2-ST plasmid DNA. hSyn-driven expression of ChrimsonR fused to mRuby2 fluorophore and targeted to the neuronal soma and proximal dendrites for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Hillel Adesnik

Pegard et al Nat Commun. 2017 Oct 31;8(1):1228. doi:

Sept. 12, 2018

Academic Institutions and Nonprofits only

#34912-AAV5

Ready-to-use AAV5 particles produced from paavCAG-post-mGRASP-2A-dTomato (#34912). In addition to the viral particles, you will also receive purified paavCAG-post-mGRASP-2A-dTomato plasmid DNA. CAG-driven expression of post-synaptic mGRASP-2A-dTomato for synaptic connectivity mapping. These AAV preparations are suitable purity for injection into animals.

Jinhyun Kim

Kim et al Nat Methods. 2011 Dec 4;9(1):96-102. doi

Aug. 7, 2025

Academic Institutions and Nonprofits only

#26966-AAV5

Ready-to-use AAV5 particles produced from pAAV-Ef1a-DIO eNpHR 3.0-EYFP (#26966). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO eNpHR 3.0-EYFP plasmid DNA. EF1a-driven, cre-dependent eNpHR 3.0-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Gradinaru et al Cell. 2010 Apr 2. 141(1):154-65.

Feb. 14, 2018

Academic Institutions and Nonprofits only